Secretory IgA (sIgA) plays a critical role in providing protection against infection at the mucosal surfaces. Normally, sIgA is the product of two different cell types with heavy, light, and J chains produced by the plasma cells, whereas secretory component (SC), a cleavage product of the polymeric immunoglobulin receptor (pIgR), is added during the transit of dimeric IgA through the epithelial cell layer. In the current study, by introducing a gene for the processed form of SC into a cell line that produces dimeric IgA, we have succeeded in creating a single cell that is able to produce and secrete covalently joined sIgA. To our knowledge, this is the first time it has been possible to efficiently produce large quantities of sIgA of defined specificity in mammalian cells. The sIgA made using this approach has great potential as an immunotherapeutic.Secretory IgA (sIgA) provides the first line of immune defense at the mucosal surfaces of the gastrointestinal, respiratory, and genitourinary tracts, where more than 95% of infections are initiated. In vivo, sIgA is the product of two different cell types, the plasma cell and the epithelial cell (1, 2). Plasma cells synthesize and assemble ␣ H chains and L chains with J chain into polymeric IgA. The polymeric IgA secreted by the plasma cell binds to the polymeric Ig receptor (pIgR) expressed on the basolateral surface of the mucosal epithelium. The IgA-pIgR complex is transcytosed to the apical surface; during transit a disulfide bond is formed between the IgA and the pIgR. At the apical surface, an unknown enzyme cleaves between the ectoplasmic domain [also known as secretory component (SC)] and the transmembrane domain, releasing the IgA-SC complex into external secretions.